CG Oncology Announces Board and Compensation Changes

Ticker: CGON · Form: 8-K · Filed: Jul 11, 2025 · CIK: 1991792

Cg Oncology, Inc. 8-K Filing Summary
FieldDetail
CompanyCg Oncology, Inc. (CGON)
Form Type8-K
Filed DateJul 11, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: board-changes, executive-compensation

TL;DR

CG Oncology shakes up board, adjusts exec pay.

AI Summary

CG Oncology, Inc. announced on July 7, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of a director and the election of a new director, along with updates to compensatory arrangements for certain officers.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and leadership stability.

Key Numbers

  • 001-41925 — Commission File Number (SEC File Number for CG Oncology, Inc.)
  • 37-1611499 — IRS Employer Identification No. (EIN for CG Oncology, Inc.)

Key Players & Entities

  • CG Oncology, Inc. (company) — Registrant
  • July 07, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 400 Spectrum Center Drive Suite 2040 (address) — Principal Executive Offices
  • Irvine, California (location) — Principal Executive Offices City and State
  • 92618 (zip_code) — Principal Executive Offices Zip Code
  • (949) 409-3700 (phone_number) — Registrant's Telephone Number

FAQ

What specific changes were made to the board of directors?

The filing indicates the departure of a director and the election of a new director.

What is the date of the earliest event reported in this 8-K?

The date of the earliest event reported is July 07, 2025.

Where are CG Oncology, Inc.'s principal executive offices located?

The principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, California, 92618.

What is the company's Commission File Number?

The company's Commission File Number is 001-41925.

What other items are covered by this 8-K filing besides director changes?

This filing also covers compensatory arrangements of certain officers.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 11, 2025 regarding CG Oncology, Inc. (CGON).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.